Practical Guidance continues to expand its collection of workflow-focused legal resources with the March 2026 update. This release introduces new templates, trackers, practice notes, and jurisdiction-specific...
How AI legal issues are being addressed with practical guidance The new generation of AI-related legal issues are inherently cross-disciplinary, implicating corporate law, intellectual property, data...
Legal teams continue to face increased pressure to manage evolving regulatory requirements, shifting case law, and growing client expectations. The February 2026 update to Practical Guidance reflects these...
Summary of Sections Real Market Data in Enhanced M&A Templates at Your Fingertips Addressing the Competitive Landscape Rollout Conclusion M&A practitioners know that drafting...
LexisNexis® Practical Guidance continues to empower legal professionals with fresh, actionable insights and resources. The July 2025 update delivers a wide range of new legal tools, regulatory trackers...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
Hear expert commentary from Tom Irving and Michelle O’Brien of the Marbury Law Group on the risk generic drug companies face when utilizing a skinny label in the aftermath of the Federal Circuit’s decision in Glaxosmithkline LLC v. Teva Pharm. USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021). This video discusses the evidence the court relied upon in finding induced infringement in this case and lessons for avoiding infringement.
Watch now »Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+